Valsartan combination therapy in the management of hypertension – patient perspectives and clinical utility

David T Nash1
Michael S McNamara2

1Syracuse Preventive Cardiology, Syracuse, New York, USA; 2Oxford PharmaGenesis Inc., Newtown, Pennsylvania, USA

Abstract: The morbidity and mortality benefits of lowering blood pressure (BP) in hypertensive patients are well established, with most individuals requiring multiple agents to achieve BP control. Considering the important role of the renin-angiotensin-aldosterone system (RAAS) in the pathophysiology of hypertension, a key component of combination therapy should include a RAAS inhibitor. Angiotensin receptor blockers (ARBs) lower BP, reduce cardiovascular risk, provide organ protection, and are among the best tolerated class of antihypertensive therapy. In this article, we discuss two ARB combinations (valsartan/hydrochlorothiazide [HCTZ] and amlodipine/valsartan), both of which are indicated for the treatment of hypertension in patients not adequately controlled on monotherapy and as initial therapy in patients likely to need multiple drugs to achieve BP goals. Randomized, double-blind studies that have assessed the antihypertensive efficacy and safety of these combinations in the first-line treatment of hypertensive patients are reviewed. Both valsartan/HCTZ and amlodipine/valsartan effectively lower BP and are well tolerated in a broad range of patients with hypertension, including difficult-to-treat populations such as those with severe BP elevations, prediabetes and diabetes, patients with the cardiometabolic syndrome, and individuals who are obese, elderly, or black. Also discussed herein are patient-focused perspectives related to the use of valsartan/HCTZ and amlodipine/valsartan, and the rationale for use of single-pill combinations as one approach to enhance patient compliance with antihypertensive therapy.

Keywords: amlodipine, combination therapy, hydrochlorothiazide, hypertension, valsartan

Introduction

Almost one in three adults in the United States has hypertension,1 and it remains a significant risk factor for cardiovascular disease.1,2 Hypertension is associated with substantial morbidity and mortality.3 Target organs that may be affected include the heart, brain, vasculature, kidneys, and eyes. Persistent blood pressure (BP) elevation may result in an acceleration of atherosclerosis, coronary heart disease, heart failure, and renal failure.3 Although not fully established, there are also numerous reports of a possible relationship between hypertension and an increased risk of cognitive decline and vascular dementia.4 Hypertension is perhaps the most important individual and societal health burden in terms of costs and loss of quality-adjusted life years.5 Although in recent years the proportion of hypertensive patients receiving treatment and the rate of BP control have increased, control rates still remain low.6 Results of the National Health and Nutrition Examination Survey (2003–2004) indicate that only approximately 37% of all hypertensive patients are controlled (systolic blood pressure [SBP]/diastolic blood pressure [DBP] <140/90 mmHg if nondiabetic or <130/80
mmHg if diabetic). Even among treated hypertensive patients, control rates are only about 57% and substantially lower among diabetics (38%).

The management of hypertension is complicated by the fact that most of this population has additional comorbidities/cardiovascular risk factors.7–11

It is recommended that lifestyle interventions (smoking cessation, weight loss, exercise, reductions in alcohol, salt, and fat intake, and increased fruit/vegetable consumption) be instituted whenever appropriate in all hypertensive patients.2,12 Unfortunately, long-term compliance with such measures is low,2 although well-designed community-based efforts were shown to reduce BP, to improve lifestyle choices and health habits, and to reduce levels of cardiovascular risk in the population.13,14 In addition to lifestyle interventions, most hypertensive patients will require antihypertensive therapy with a combination of agents to reach BP goals.2,15 For example, in ASCOT-BPLA, nearly 90% of participants were on multiple antihypertensive agents by the end of the trial.16

Antihypertensive drugs of different classes can be combined if: they have different and complementary mechanisms of action; the efficacy of the combination is greater than that of either component; and the complementary mechanisms of action lead to a favorable tolerability profile. The advantages of this approach are that: low doses of the individual components can be used; the process of searching for effective monotherapies in patients at high risk can be avoided; and the BP target level can be reached more quickly. The need for combination therapy is particularly relevant for high-risk hypertensive patients such as those with diabetes or chronic kidney disease. A coexistent diagnosis of hypertension and diabetes increases the risk of adverse cardiovascular and renal outcomes, and the increased risk extends down to SBP/DBP levels as low as 127/83 mmHg.17

Results of numerous landmark clinical trials such as the VA Cooperative,18,19 HDFP,20 SHEP,21 Syst-Eur,22 CONVINCE,23 INVEST,24 SCOPE,25 CAMELOT,26 VALUE,27 ASCOT-BPLA,16 and ACCOMPLISH28 have demonstrated that several classes of antihypertensive agents, administered alone or most often in combination, can reduce BP and improve cardiovascular outcomes. Some evidence suggests that lowering elevated BP with antihypertensive therapy may also have a protective effect against vascular dementia and cognitive decline.4,29 Although a lack of benefit in this regard has also been reported, there is no empirical evidence to suggest that treatment of hypertension has negative effects on brain function, including in the very elderly.30,31 Antihypertensive regimens that suppress the renin-angiotensin-aldosterone system (RAAS) are of particular interest given the important role of the RAAS in cardiovascular and renal disorders and the ability of RAAS inhibitors to not only lower BP and reduce cardiovascular risk but to also provide organ protection.32,33 Angiotensin receptor blockers (ARBs) have BP-lowering34 and cardiorenal protective effects35–39 that are similar to those of angiotensin-converting enzyme (ACE) inhibitors, but with better tolerability.34 When ARBs are administered as part of combination therapy, an optimal approach is to include a diuretic or calcium channel blocker (CCB).40

In this review, we discuss the key studies that have assessed the antihypertensive effects of valsartan, one of the most extensively studied ARBs, when used in combination with the diuretic hydrochlorothiazide (HCTZ) or the CCB amlodipine in the first-line treatment of hypertension and its associated comorbidities. The studies described were not designed to assess clinical outcomes or effects on cognitive function. To date, studies involving amlodipine/valsartan have focused on BP control; outcomes studies are not available. In addition, no outcomes studies are available on the first-line use of valsartan/HCTZ, although a study in high-risk hypertensive patients in which HCTZ was a possible add-on therapy to valsartan demonstrated the benefits of this treatment on cardiovascular morbidity and mortality.27 Valsartan therapy has also shown benefits on hard endpoints in nonhypertensive populations including patients with chronic heart failure41 and postmyocardial infarction.42 The latter part of this article presents patient-focused perspectives related to the use of valsartan/HCTZ and amlodipine/valsartan, along with a discussion of compliance in the treatment of hypertension and the rationale for the use of single-pill combinations.

### Valsartan combination therapies

#### Valsartan/hydrochlorothiazide (HCTZ)

The combination of valsartan/HCTZ is indicated in patients whose BP is not adequately controlled on monotherapy, and it is now also approved for use as first-line treatment in patients likely to need multiple drugs to achieve their BP goals. All studies discussed employed a randomized, double-blind design and, in all cases, study medication was administered once daily. A section on safety and tolerability follows the discussion of efficacy.

#### Mild to moderate hypertension

##### Phase III studies

Two 8-week, placebo-controlled studies compared the antihypertensive efficacy of valsartan/HCTZ versus monotherapy. In one study, 871 patients with mild to moderate hypertension, defined as DBP
95–115 mmHg, were evaluated. Patients received valsartan/HCTZ 80/12.5 mg, 80/25 mg, 160/12.5 mg, or 160/25 mg; valsartan 80 mg or 160 mg; HCTZ 12.5 mg or 25 mg; or placebo for 8 weeks. The primary endpoint was change in mean seated DBP (MSDBP) from baseline. Placebo-subtracted changes in mean seated SBP (MSSBP)/MSDBP from baseline to 8 weeks were −14.6/−7.7 mmHg, −19.2/−11.2 mmHg, −15.8/−9.4 mmHg, and −20.5/−11.2 mmHg with valsartan/HCTZ 80/12.5 mg, 80/25 mg, 160/12.5 mg, and 160/25 mg, respectively; −6.9/−4.5 mmHg and −10.2/−5.3 mmHg with valsartan 80 mg and 160 mg, respectively; and −5.4/−3.0 mmHg and −10.8/−5.2 mmHg with HCTZ 12.5 mg and 25 mg, respectively. Combination therapy provided significantly greater antihypertensive efficacy relative to placebo and the corresponding monotherapies (P < 0.05).

The second placebo-controlled study investigated the antihypertensive efficacy of valsartan and HCTZ alone and in combination at doses up to 320/25 mg in 1346 patients with DBP ≥ 95 mmHg and <110 mmHg. Patients received valsartan/HCTZ 160/12.5 mg, 320/12.5 mg, or 320/25 mg; valsartan 160 mg or 320 mg; HCTZ 12.5 mg or 25 mg; or placebo for 8 weeks. The primary endpoint was change in MSDBP from baseline. Changes in MSSBP/MSDBP from baseline to 8 weeks were −20.3/−15.2 mmHg, −21.7/−15.0 mmHg, and −24.7/−16.6 mmHg with valsartan/HCTZ 160/12.5 mg, 320/12.5 mg, and 320/25 mg, respectively; −14.5/−11.7 mmHg and −13.7/−11.3 mmHg with valsartan 160 mg and 320 mg, respectively; −11.1/−9.0 mmHg and −14.5/−10.8 mmHg with HCTZ 12.5 mg and 25 mg, respectively; and −5.9/−7.0 mmHg with placebo. Responder rates (MSDBP < 90 mmHg or ≥10 mmHg reduction from baseline) and BP control rates (MSSBP/MSDBP <140/90 mmHg) at endpoint are shown in Figure 1. For all efficacy parameters, combination therapy provided significantly greater antihypertensive efficacy relative to placebo and the corresponding monotherapies (P < 0.05).

**Phase IV studies**

The VELOCITY study assessed the BP reduction when initiating treatment with valsartan/HCTZ compared with initiating treatment with low-dose, conventional valsartan monotherapy (80 mg) or standard-dose valsartan monotherapy (160 mg) in 648 patients with mild to moderate hypertension (SBP/DBP 150–179/90–109 mmHg), including...
patients with diabetes and metabolic syndrome.\textsuperscript{45} Patients received valsartan/HCTZ 160/12.5 mg, valsartan 80 mg, or valsartan 160 mg for 6 weeks. Patients were up-titrated after 2 and 4 weeks to the next dosage level (maximum for valsartan/HCTZ: 160/25 mg) only if MSSBP/MSDBP remained $>$140/90 mmHg. The primary endpoint was change in MSSBP from baseline to 2, 4, and 6 weeks. The level of BP reduction achieved in patients who began treatment with valsartan monotherapy (conventional step therapy) never caught up to the level achieved in patients who started with valsartan/HCTZ. Changes in MSSBP/MSDBP from baseline to 6 weeks were $-27.1/-14.9$ mmHg with valsartan/HCTZ, $-20.1/-10.8$ mmHg with valsartan 80 mg, and $-23.1/-11.7$ mmHg with valsartan 160 mg. Results favored combination therapy over either dose of valsartan alone ($P < 0.05$).

The PROMPT study compared the antihypertensive efficacy of valsartan/HCTZ (first- and second-line use) and amlodipine/HCTZ for maximizing BP control in 1285 patients with uncontrolled hypertension.\textsuperscript{46} Patients who had mild hypertension (SBP/DBP 140–159/90–99 mmHg) and were naïve to antihypertensive therapy started on valsartan 160 mg or amlodipine 5 mg. Treatment-naïve patients with moderate hypertension (SBP/DBP 160–179/100–109 mmHg) and those uncontrolled on current antihypertensive monotherapy started on valsartan/HCTZ 160/12.5 mg or amlodipine 10 mg. At 4, 8, and 11 weeks, patients not achieving BP control were uptitrated (maximum: valsartan/HCTZ 320/25 mg or amlodipine/HCTZ 10/25 mg). Uptitration was mandatory for MSSBP/MSDBP $\geq 140/90$ mmHg. The treatment duration was 14 weeks. BP control rates (MSSBP/MSDBP $< 140/90$ mmHg) at 14 weeks, the primary endpoint, were 78.8% with valsartan-based treatment and 67.8% with amlodipine-based treatment ($P < 0.0001$). Significant differences in favor of valsartan-based therapy were observed as early as 8 weeks (70.3% vs 64.5%, $P < 0.05$). Results were consistent, regardless of whether patients were treatment naïve or had failed previous monotherapy. Thus, the valsartan-based strategy was superior to the amlodipine-based strategy for achieving BP control.

**Moderate hypertension**

The EVALUATE study examined the antihypertensive efficacy of valsartan/HCTZ and amlodipine/HCTZ on the reduction of ambulatory BP (ABP) in 482 patients with moderate hypertension (SBP 160–200 mmHg).\textsuperscript{47} EVALUATE was designed to mirror the treatment arms of the VALUE outcomes study. In VALUE, there was greater BP reduction observed in the amlodipine arm compared with the valsartan arm in the first 6 months that accounted for the differences in outcomes favoring amlodipine.\textsuperscript{27} It is discussed that these findings may have been due to slow titration and use of a less than maximal dose of valsartan (160 mg),\textsuperscript{48} which is half of what is currently considered as the maximum recommended dose. Thus, in EVALUATE, patients received valsartan 160 mg force-titrated to valsartan/HCTZ 160/12.5 mg at 2 weeks and 320/25 mg at 6 weeks or amlodipine 5 mg force-titrated to 10 mg at 2 weeks and amlodipine/HCTZ 10/25 mg at 6 weeks.\textsuperscript{47} The treatment duration was 10 weeks. The primary endpoint was change in mean 24-hour ambulatory SBP (ASBP) from baseline to 10 weeks. Changes in mean 24-hour ASBP/ambulatory DBP (ADBp) from baseline to 10 weeks were $-21.1/-12.5$ mmHg with valsartan/HCTZ and $-18.1/-9.9$ mmHg with amlodipine/HCTZ ($P < 0.01$). As shown in Figure 2, valsartan/HCTZ provided greater antihypertensive efficacy over the entire 24-hour monitoring period. ABP control rates (mean 24-hour ASBP/ADBp $< 130/80$ mmHg) at 10 weeks were 54.3% with valsartan/HCTZ and 42.7% with amlodipine/HCTZ ($P < 0.05$). These data show that valsartan/HCTZ provides reduction in ABP that is superior to that achieved with amlodipine/HCTZ.

**Severe hypertension**

In the CDITT study, the antihypertensive efficacy of initiating therapy with combination valsartan/HCTZ versus valsartan monotherapy was examined in 608 patients with severe hypertension, defined as SBP $\geq 140$ mmHg and <200 mmHg plus DBP $\geq 110$ mmHg and <120 mmHg.\textsuperscript{49} Patients received valsartan/HCTZ 160/12.5 mg force-titrated to 160/25 mg at 2 weeks and 320/25 mg at 4 weeks or valsartan 160 mg force-titrated to 320 mg at 2 weeks and sham-titrated to 320 mg at 4 weeks. The treatment duration was 6 weeks. BP control rates (MSSBP/MSDBP $< 140/90$ mmHg) at 4 weeks, the primary endpoint, were 39.6% with valsartan/HCTZ and 21.8% with valsartan ($P < 0.0001$). The corresponding results at 6 weeks were 48.2% and 27.2% ($P < 0.0001$). Changes in MSSBP/MSDBP from baseline to 4 weeks and 6 weeks are shown in Figure 3. Control rates and BP reductions consistently favored combination therapy over monotherapy, regardless of age (<65 or $\geq 65$ years), race (white or black), or severity of baseline MSSBP ($<180$ or $\geq 180$ mmHg).

**Influence of valsartan on the metabolic effects of HCTZ in the combination valsartan/HCTZ**

The MADE-ITT study evaluated the effects of valsartan and HCTZ alone and in combination on insulin sensitivity and inflammatory/metabolic biomarkers in 566 patients...
with prediabetes, obesity, hypertension (SBP/DBP 130–160/85–100 mmHg) and the cardiometabolic syndrome. Patients received valsartan/HCTZ 160/12.5 mg force-titrated to 320/25 mg at 2 weeks, valsartan 160 mg force-titrated to 320 mg at 2 weeks, or HCTZ 12.5 mg force-titrated to 25 mg at 2 weeks. The treatment duration was 16 weeks. There were no significant differences among the 3 treatment groups for the primary endpoint, which was change in homeostasis model assessment-insulin resistance (HOMA-IR) from baseline to 16 weeks. However, valsartan attenuated the negative metabolic effects of HCTZ (increases in triglyceride and hemoglobin). At 16 weeks, treatment with HCTZ increased triglyceride levels by 0.3 mmol/L and hemoglobin A1c levels by 0.2%, whereas valsartan and valsartan/HCTZ had less of an effect on these parameters. Changes in MSSBP/MSDBP from baseline to 16 weeks were significantly greater with combination therapy (−20/−12 mmHg) than with valsartan (−14/−9 mmHg) or HCTZ (−12/−7 mmHg) ($P < 0.0001$). These findings support the initial use of valsartan/HCTZ in this high-risk population.

The VITAE study was undertaken to confirm the findings from MADE-ITT using actual glucose and insulin measures (both fasting and 2 hour). Specifically, the metabolic and antihypertensive effects of valsartan/HCTZ versus amlodipine/HCTZ in 412 prediabetic, obese patients with mild to moderate hypertension (SBP/DBP 150–179/<110 mmHg) were investigated. Patients received valsartan/HCTZ 160/12.5 mg force-titrated to 320/12.5 mg at 4 weeks and 320/25 mg at 8 weeks, or HCTZ 12.5 mg force-titrated to 25 mg at 4 weeks, amlodipine/HCTZ 5/25 mg at 8 weeks, and amlodipine/HCTZ 10/25 mg at 12 weeks. The treatment duration was 16 weeks. The primary endpoint was change in MSSBP from baseline. Changes in MSSBP/MSDBP from baseline to 16 weeks were −30.6/−14.0 mmHg with valsartan/HCTZ and −28.3/−12.7 mmHg with amlodipine/HCTZ ($P = NS$). Fasting and 2-hour glucose increased with amlodipine/HCTZ compared with valsartan/HCTZ ($P < 0.01$), resulting in a greater percentage of patients with impaired fasting glucose or impaired oral glucose tolerance test. In the valsartan/HCTZ group, the percentage of patients with impaired fasting glucose was 34% at baseline and 38% at 16 weeks. Corresponding results for impaired oral glucose tolerance test were 36% and 29%. Conversely, the percentage of amlodipine/HCTZ-treated patients with impaired fasting glucose increased from 38% to 50% during this time as did the percentage with impaired oral glucose tolerance test (from 34% to 48%). New-onset diabetes occurred in more patients receiving amlodipine/HCTZ compared with valsartan/HCTZ (11% vs 2%, $P < 0.05$). Thus, compared with amlodipine/HCTZ, valsartan/HCTZ reduced progression towards impaired fasting glucose, impaired glucose tolerance, and new-onset diabetes in this high-risk population.

Figure 2 Changes in ambulatory systolic and diastolic blood pressure from baseline over a 24-hour period after 10 weeks of treatment in a study of 482 patients with moderate hypertension. Reprinted with permission from Lacourcière Y, Wright Jr JT, Samuel R, Zappe D, Purkayastha D, Black HR. Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study. Blood Press Monit. 2009; 14(3):112–120. Copyright © 2009 Lippincott Williams & Wilkins.

**Abbreviations:** AMLO, amlodipine; BP, blood pressure; HCTZ, hydrochlorothiazide; VAL, valsartan.
Switch study

Diuretics are recommended as first-line therapy for the treatment of hypertension. A study was conducted to assess whether, in patients uncontrolled on diuretic monotherapy, it is a better strategy to switch to dual therapy or double the dose of diuretic. The Val-DICTATE study included 291 patients with hypertension whose BP remained uncontrolled (SBP > 140 and <180 mmHg plus DBP > 90 and <110 mmHg) after 4 weeks of therapy with low-dose HCTZ (12.5 mg). These patients received valsartan/HCTZ (160/12.5 mg) or double the dose of HCTZ (25 mg) for another 4 weeks. At study end, a significantly greater percentage of patients achieved the BP goal (MSSBP/MSDBP < 140/90 mmHg), the primary endpoint, in the valsartan/HCTZ group compared with the high-dose HCTZ group (36.6% vs 15.9%, \(P < 0.0001\)). Similarly, changes in MSSBP/MSDBP at study end were significantly greater in the combination therapy arm compared with the diuretic monotherapy arm (\(-12.4/\sim 7.5\) mmHg vs \(-5.6/\sim 2.1\) mmHg, \(P < 0.0001\)). Thus, in patients whose BP was inadequately...
controlled on low-dose HCTZ (12.5 mg), switching to valsartan/HCTZ 160/12.5 mg was a better antihypertensive strategy than doubling the dose of HCTZ.

Other studies
The results of several open-label studies also support the antihypertensive efficacy of valsartan/HCTZ.44,53–58

Safety and tolerability
The combination of valsartan/HCTZ is well tolerated and adverse events are generally mild and transient. A meta-analysis of the results of 9 randomized, double-blind, placebo-controlled, hypertension studies (N = 4278) of once-daily valsartan 80, 160, or 320 mg or valsartan/HCTZ 80/12.5, 160/12.5 mg, 160/25 mg, 320/12.5 mg, or 320/25 mg given for 4 to 8 weeks found that the most common adverse event was dizziness (7.3% to 16.0% in the valsartan/HCTZ groups vs 2.4% to 5.2% with valsartan monotherapy and 2.8% with placebo).59 The incidence of headache was similar across all dose groups including placebo. The rate of discontinuation due to adverse events was generally low at all dose levels (eg, 3.0% with valsartan/HCTZ 320/25 mg vs 2.7% with placebo).60 Data suggest that the incidence of hypokalemia may be lower with valsartan/HCTZ compared with HCTZ alone (1.8% to 6.1% vs 7.1% to 13.3%).61 and that valsartan may attenuate the negative metabolic effects of HCTZ in patients with prediabetes, obesity, hypertension, and the cardiometabolic syndrome (see MADE-ITT study results described previously).62 Valsartan/HCTZ was associated with a lower incidence of peripheral edema compared with amlodipine/HCTZ across the studies presented previously (1.5% to 3.3% vs 9.7% to 22.4%).46,47,51

Amlodipine/valsartan
The combination of amlodipine/valsartan is indicated for the treatment of hypertension in patients not adequately controlled on monotherapy and as initial therapy in patients likely to need multiple drugs to achieve their BP goals. All studies discussed in this section employed a randomized, double-blind design and, in all cases, study medication was administered once daily. A section on safety and tolerability follows the discussion of efficacy.

Factorial phase III studies in mild to moderate hypertension
Two placebo-controlled studies compared the antihypertensive efficacy of various combinations of amlodipine/valsartan versus monotherapy with these agents in 3161 patients with mild to moderate hypertension (DBP ≥ 95 and <110 mmHg).60 In study 1, 15 factorial treatment regimens were used and, in study 2, 6 regimens were used. The primary endpoint was change in MSDBP from baseline to 8 weeks. Apart from a few combinations that included amlodipine 2.5 mg, the combination regimens in both studies were associated with significantly greater reductions in MSSBP and MSDBP compared with their individual components and placebo (P < 0.05). A positive dose-response relationship was observed for all combinations, and the highest response rate (MSDBP < 90 mmHg or a ≥ 10 mmHg reduction from baseline) in study 1 was associated with the highest dose of combination therapy (91.3% for amlodipine/valsartan 5/320 mg). In contrast, amlodipine 5 mg, valsartan 320 mg, and placebo as monotherapy were associated with response rates of 71.9%, 73.4%, and 40.9%, respectively. In study 2, the 2 combination therapy regimens were associated with similar response rates (amlodipine/valsartan 10/160 mg, 88.5%; amlodipine/valsartan 10/320 mg, 87.5%). Amlodipine 10 mg was associated with a response rate of 86.9%; valsartan 160 mg and 320 mg were associated with response rates of 74.9% and 72.0%, respectively. Placebo was associated with a response rate of 49.3%.63 Subgroup analyses of the results of these studies, conducted according to the severity of hypertension (mild or moderate), age (< 65 or ≥ 65 years) and race (white or black), showed that reductions in MSSBP and MSDBP in the various subgroups were consistent with the findings from the overall study population.64

Phase IV studies in moderate hypertension
Destro and colleagues investigated the antihypertensive efficacy of amlodipine/valsartan and amlodipine alone in 646 patients with moderate hypertension (SBP ≥ 160 mmHg and < 200 mmHg).65 Patients received amlodipine/valsartan 5/160 mg force-titrated to 10/160 mg at 2 weeks or amlodipine 5 mg force-titrated to 10 mg at 2 weeks. HCTZ was optionally added at 4 weeks in patients if MSSBP ≥ 130 mmHg. The treatment duration was 8 weeks. Changes in MSSBP from baseline to 4 weeks (prior to possible addition of HCTZ), the primary endpoint, were −30.1 mmHg with amlodipine/valsartan and −23.5 mmHg with amlodipine (P < 0.0001). In patients with baseline MSSBP ≥ 180 mmHg, the corresponding results were −40.1 mmHg and −31.7 mmHg (P < 0.01). Results were consistent across various patient subgroups, including patients with diabetes, the elderly (≥ 65 years), patients with isolated systolic hypertension, those with body mass index ≥ 30 kg/m², and patients of different races/ethnicity (white, black, or Hispanic) (Figure 4). BP control
rates (MSSBP/MSDBP <140/90 mmHg) at 4 weeks were 45.3% with amlodipine/valsartan and 23.8% with amlodipine (P < 0.0001).

Poldermans and colleagues examined the antihypertensive efficacy of amlodipine/valsartan compared with lisinopril/HCTZ in 130 patients with moderate hypertension (DBP ≥ 110 mmHg and <120 mmHg). Patients received amlodipine/valsartan 5/160 mg or lisinopril/HCTZ 10/12.5 mg for 2 weeks. Thereafter, up-titration to 10/160 mg and 20/12.5 mg, respectively, occurred for MSDBP ≥ 90 mmHg. The treatment duration was 6 weeks. The primary endpoint was safety, but post-hoc efficacy endpoints included change in MSSBP/MSDBP from baseline and BP control rates (MSSBP/MSDBP < 140/90 mmHg). Both regimens were deemed efficacious. Changes in MSSBP/MSDBP from baseline to study end were −35.8/−28.6 mmHg with amlodipine/valsartan and −31.8/−27.6 mmHg with lisinopril/HCTZ. BP control rates at this time were 67.2% and 56.1%, respectively.

**Phase IV study in black patients with moderate hypertension**

Blacks patients are usually considered a difficult-to-treat population. The EX-STAND study assessed the antihypertensive efficacy of initiating treatment with amlodipine/valsartan compared with amlodipine monotherapy in 572 black patients with moderate hypertension (SBP ≥ 160 and <200 mmHg). Patients received amlodipine/valsartan 5/160 mg force-titrated to 10/160 mg at 2 weeks or amlodipine 5 mg force-titrated to 10 mg at 2 weeks. If MSSBP was ≥ 130 mmHg at 4 weeks, the doses in the amlodipine/valsartan arm were increased to 10/320 mg and placebo was added to the amlodipine arm. At 8 weeks, HCTZ was optionally added to both treatment groups for patients with MSSBP ≥ 130 mmHg. The treatment duration was 12 weeks. Changes in MSSBP from baseline to 8 weeks (prior to possible addition of HCTZ), the primary endpoint, were −33.3 mmHg with amlodipine/valsartan and −26.6 mmHg with amlodipine (P < 0.0001). Significant differences in favor of initial combination therapy were observed as early as 2 weeks and also were seen at 4 and 12 weeks (Figure 5). Combination therapy provided greater reductions in MSSBP from baseline to 8 weeks across various patient subgroups, including the elderly (≥65 years), patients with isolated systolic hypertension, diabetics, those with body mass index ≥ 30 kg/m², patients who were black/Hispanic, and patients with baseline MSSBP ≥ 180 mmHg. BP control rates (MSSBP/MSDBP < 140/90 mmHg) at

![Figure 4 Least-squares mean changes in mean seated systolic blood pressure (MSSBP) from baseline after 4 weeks of treatment across various patient subgroups with moderate hypertension. Elderly patients were ≥65 years of age.](https://www.dovepress.com/)


**Abbreviations:** AMLO, amlodipine; BMI, body mass index; ISH, isolated systolic hypertension; SeM, standard error of the mean; Vals, valsartan.
8 weeks were 49.8% with amlodipine/valsartan and 30.2% with amlodipine ($P < 0.0001$).

**Phase IIIb-IV switch studies in patients previously uncontrolled with monotherapy**

Allemann and colleagues evaluated the antihypertensive efficacy of a strategy involving a direct switch to amlodipine/valsartan in 894 patients whose BP was uncontrolled by previous monotherapy (EX-FAST study). Patients were switched directly to amlodipine/valsartan 5/160 mg or 10/160 mg for 16 weeks. At 8 weeks, HCTZ was added to both treatment groups for patients whose BP was not controlled (MSSBP/MSDBP $\geq 140/90$ mmHg in nondiabetic patients, $\geq 130/80$ mmHg in patients with diabetes). BP control rates at 16 weeks, the primary endpoint, were similar in the 2 treatment groups: 72.7% with amlodipine/valsartan 5/160 mg ($\pm$ HCTZ) and 74.8% with amlodipine/valsartan 10/160 mg ($\pm$ HCTZ). Incremental reductions in MSSBP/MSDBP from baseline to 16 weeks were significantly greater with the higher dose ($-20.0/-11.6$ mmHg) than with the lower dose ($-17.5/-10.4$ mmHg) ($P < 0.01$). BP control rates at 8 weeks (prior to possible addition of HCTZ) also were significantly greater with the higher dose (76.4%) than with the lower dose (71.1%) ($P < 0.05$). Subgroup analysis revealed that the antihypertensive efficacy of amlodipine/valsartan was well maintained regardless of previous antihypertensive monotherapy (Figure 6), baseline hypertension severity, diabetic status, body mass index, age, gender, or race.

The antihypertensive efficacy of switching patients whose BP was not controlled on valsartan 160 mg monotherapy to amlodipine/valsartan 5/160 mg or 10/160 mg was studied in 947 patients with mild or moderate hypertension (DBP $\geq 95$ and $\leq 110$ mmHg). Patients received amlodipine/valsartan 5/160 mg, amlodipine/valsartan 10/160 mg, or continued on valsartan 160 mg for 8 weeks. The primary endpoint was change in MSDBP from baseline to study end. Changes in MSSBP/MSDBP from baseline to study end were significantly greater with lower-dose combination therapy ($-12.2/-9.6$ mmHg) and higher-dose combination therapy ($-14.3/-11.5$ mmHg) compared with valsartan alone ($-8.3/-6.7$ mmHg) ($P < 0.0001$). The 10/160 mg combination showed significantly greater reductions in MSSBP and MSDBP than the 5/160 mg combination ($P < 0.05$). Response rates (MSDBP $< 90$ mmHg or $\geq 10$-mmHg reduction from baseline) at endpoint were significantly greater in the combination therapy groups (68% with 5/160 mg, 76.4% with 10/160 mg) compared with valsartan alone (61.8%).

---


**Abbreviations:** AMLO, amlodipine; HCTZ, hydrochlorothiazide; SeM, standard error of the mean; VAL, valsartan.
81% with 10/160 mg) than in the monotherapy group (57%) ($P < 0.01$). Both combination therapies were more effective than monotherapy regardless of age (<65 or ≥65 years).

**Other studies**

The results of several open-label studies also support the antihypertensive efficacy of amlodipine/valsartan.67–72 Of note, one of the trial designs involved switching patients whose BP was not controlled on a free combination (amlodipine plus olmesartan) to a single-pill combination (amlodipine plus valsartan).71 Treatment with the single-pill combination was associated with a further reduction in BP of 7.9/9.1 mmHg, with 42% of previously uncontrolled patients achieving BP < 140/90 mmHg. The authors concluded that these results may have been related, at least in part, to improved patient compliance, although this was not specifically assessed in the study. The issues of compliance with antihypertensive therapy and the potential role of single-pill combination therapy are discussed in more detail later.

**Safety and tolerability**

Amlodipine/valsartan was well tolerated in the above-mentioned clinical studies. Most adverse events were mild or moderate in severity and did not result in discontinuation. Overall, the most frequent adverse event was peripheral edema, which is a well-known side effect of CCBs. CCBs cause greater dilation of the arteriolar rather than the venous circulation, giving rise to an increased transcapillary gradient and capillary leakage.73 The addition of a RAAS blocker may help to negate this effect because it causes dilation of both arterial and venous capillary beds, thus bringing transcapillary pressure back to normal. One randomized, double-blind study assessed the incidence of peripheral edema as a co-primary endpoint in 1183 patients not adequately controlled on amlodipine 5 mg.74 Peripheral edema was evaluated at every clinic visit and was based on spontaneous reports by the patients and on the presence of signs of edema on physical examination of the patient by the investigator. Over the first 8 weeks of the study, patients received either amlodipine/valsartan 5/160 mg or double the dose of amlodipine (10 mg). During this time, peripheral edema was reported in 31.1% of patients on high-dose amlodipine compared with only 6.6% of patients on combination therapy ($P < 0.001$). After 8 weeks of therapy, 484 patients previously on high-dose amlodipine were switched to amlodipine/valsartan 5/160 mg for another 4 weeks. Of the 79 patients who had peripheral edema entering the switch phase, 44 (56%) had resolution of this adverse event during the switch phase.

**Figure 6** Changes in mean seated systolic blood pressure (MSSBP) from baseline after 8 weeks of treatment in patients whose blood pressure was uncontrolled on previous antihypertensive monotherapy. Results are shown by previous antihypertensive monotherapy. Reprinted with permission from Allemann Y, Fraile B, Lambert M, Barbier M, Ferber P, Izso JL Jr. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) study. J Clin Hypertens (Greenwich). 2008;10(3):185–194.4 Copyright © 2008 John Wiley and Sons, Inc.

**Abbreviations:** ACEI, angiotensin-converting enzyme inhibitor; AMLO, amlodipine; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; VAL, valsartan.

<table>
<thead>
<tr>
<th>Antihypertensive class prior to randomization</th>
<th>Overall</th>
<th>β-Blocker</th>
<th>CCB</th>
<th>ARB</th>
<th>ACEI</th>
<th>Diuretic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>440</td>
<td>76</td>
<td>55</td>
<td>70</td>
<td>175</td>
<td>105</td>
</tr>
<tr>
<td>Mean change in MSSBP from baseline to Week 8, mmHg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AMLO/VAL 5/160 mg</td>
<td>−17.6</td>
<td>−21.0</td>
<td>−24.3</td>
<td>−21.3</td>
<td>−17.7</td>
<td>−17.4</td>
</tr>
<tr>
<td>AMLO/VAL 10/160 mg</td>
<td>−17.5</td>
<td>−20.0</td>
<td>−21.3</td>
<td>−19.6</td>
<td>−17.5</td>
<td>−17.6</td>
</tr>
</tbody>
</table>
studies described previously, peripheral edema was reported in a slightly higher percentage of amlodipine-treated (± HCTZ) patients (8.7% to 17.6%) than amlodipine/valsartan-treated (± HCTZ) patients (5.0% to 16.7%). The occurrence of peripheral edema appeared to be related to the dose of amlodipine. The incidence of peripheral edema was low among patients treated with valsartan monotherapy (1.3% to 2.1%) or placebo (3%) in the same studies.

**Patient-focused perspectives**

Much of the difficulty of controlling high BP may be due to poor persistence and adherence with therapy as patients who are adherent are more likely to have good BP control. Poor adherence with antihypertensive therapy may lead to extra medical consultations, higher doses, or an increase in the number of medications used and possibly increased morbidity and mortality, loss of productivity, and increased health care costs. Analyses of data from the Integrated Healthcare Information Solutions (IHCIS) National Managed Care Benchmark Database indicate that patient compliance improves with simplification of pharmacotherapeutic approaches, and that use of single-pill combination therapy may improve adherence and persistence and have a positive economic impact.

For example, an analysis of the impact of multiple combination therapies on medication possession ratios (MPRs) in an antihypertensive-naive population was conducted using IHCIS data from patients treated with valsartan or valsartan/HCTZ in a single-pill combination plus amlodipine (2-pill therapy) compared with patients who received 3-pill therapy with valsartan plus HCTZ plus amlodipine. Data from 908 patients were included (2-pill therapy with valsartan plus amlodipine, n = 224; 2-pill therapy with valsartan/HCTZ plus amlodipine, n = 619; and 3-pill therapy with valsartan plus HCTZ plus amlodipine, n = 65) over a 1-year study period. MPR values obtained were 75.4%, 73.1%, and 60.5%, respectively (P < 0.01), and it was found that MPR improved with age (69.6% in the subset aged 18 to <36 years vs 75.2% in the subset aged ≥64 years, P < 0.05). Thus, in these antihypertensive-naive patients with hypertension, MPR decreased with the increase in tablets per regimen. Improved MPR was correlated with increasing age, and the results suggested that patient compliance improved with simplified pharmacotherapeutic approaches.

In addition, medical and prescription claims for hypertensive patients were identified from the IHCIS National Managed Care Benchmark Database via a retrospective cohort analysis to assess medication adherence, persistence, and costs between cohorts of patients in managed care settings using a single-pill combination of valsartan/HCTZ or the individual components. Patients who were studied had at least 110 days prior to start of study medications during which no other antihypertensive medications were prescribed, were followed for 12 months, and claims for 8711 adult patients were analyzed. Most individuals used a single-pill combination product (n = 8150, 93.6%) versus the individual components (n = 561, 6.4%). A random sample of 1628 of the single-pill combination patients showed improved values for medication adherence compared with the individual components group (62% vs 53%, P < 0.001), and persistence values were improved at both 180 days (73% vs 28%, P < 0.001) and 365 days (54% vs 19%, P < 0.001). Both prescription drug costs and medical costs were significantly lower in the single-pill combination cohort. Over 1 year, the mean total prescription costs for the individual components versus the single-pill combination were US$2050 versus US$1587, respectively, providing a mean difference of $463 (P < 0.001). Corresponding medical costs were US$3817 versus US$3343, providing a mean difference of US$474 (P < 0.001). Although unobserved systematic differences between the 2 medication groups may have existed, as with any retrospective claims database analysis, it was concluded that use of valsartan/HCTZ single-pill combination therapy in hypertension may lead to increased adherence and persistence with a positive financial impact on both prescription and total medical costs. Combination therapy with a CCB plus an ARB also was shown to be a more cost-effective lifetime antihypertensive strategy than monotherapy with either agent alone.

**Compliance in the treatment of hypertension**

Hypertension is a common and extremely treatable risk factor for major cardiovascular events and cerebrovascular events. Since together they represent a major cause of morbidity and mortality throughout the developed world, and in many developing nations, one would assume that once a large number of safe and effective medications were developed and widely distributed at reasonable costs, the problem represented by hypertension would gradually diminish to the point of being irrelevant. In fact that has not occurred, and it is useful to examine compliance and its politically correct alternative of adherence.

Any consideration must include an analysis of the problem, its consequences, and suggestive approaches to its resolution or improvement. There is little doubt about the size of the problem of poor compliance with
antihypertensive therapy. In a recent Italian study, a cohort of 445,356 hypertensive patients aged 40–80 years received their first antihypertensive prescription (monotherapy) during 1999–2002. Discontinuation was defined by the absence of any antihypertensive therapy during a 90-day period following the end of the last prescription. If during the same period a drug of a different class was added or replaced the original prescription, the treatment modification was considered combination or switching, respectively. The cumulative incidences of discontinuation, combination, and switching were 41%, 18%, and 17% at 1 year and 50%, 25%, and 19% at 5 years, and inhibitors of the RAAS were associated with the lowest rates of discontinuation. Drug choice apparently does affect the compliance with treatment options and outcomes in elderly hypertensive patients. A prospective, single-center study focused on elderly patients and utilized a full range of currently available drugs, which added to its relevance. The authors found that newer antihypertensive therapies, including ACE inhibitors and ARBs, were associated with greater persistence and better antihypertensive efficacy than older drugs. At the end of the 2-year study, patients who started on diuretics were only half as likely to be still taking their medication compared with the more modern drugs. In addition to the importance of class of antihypertensive therapy, it is critical for physicians to diagnose any cognitive impairment that may exist in the elderly patient, as this may have important implications in terms of treatment compliance.

Because hypertension control rates are unsatisfactory, the role of adherence has been examined. A variety of programs have been suggested including patient motivational factors, social support, and reminding techniques. For example, a program that included a combination of medical education, regular follow-up by pharmacists, and time-specific medication packs yielded an overall 34% improvement in medication adherence and significant reductions in SBP of 6.9 mmHg. Other approaches have included simpler dosing, various drug packaging, and provider interventions including tutorials. In general, although there are some occasional success stories, it is apparent that as yet we have not discovered the “magic bullet” that will ensure appropriate compliance.

The rationale for combination antihypertensive therapy including single-pill combinations
Control of hypertension is difficult to achieve in clinical practice, especially in high-risk patients, and so-called ‘therapeutic inertia’ derived from poorly prescribed lifestyle changes, excessive use of monotherapy, and scarce on-treatment modifications may be a significant factor. The use of combination therapy and, in particular, single-pill combinations, significantly improves BP control without increasing daily pill intake, favoring patient compliance, continuity of treatment, and lower costs to the health care system. For example, a recent retrospective analysis of medical and pharmacy claims data found that, compared with free-combination antihypertensive therapy, single-pill combination therapy resulted in 42.5% greater persistence, 22.1% greater compliance, 21.3% fewer hypertension-related hospitalizations, and 20.2% lower expenditures for hypertension-related services. Other analyses have similarly demonstrated that subjects taking single-pill combination antihypertensive therapy had significant increases in medication adherence and reductions in resource utilization relative to subjects receiving the same drug classes as separate components. A meta-analysis by Bangalore and colleagues found that single-pill combination therapy reduced the risk of medication nonadherence among hypertensive patients by 24% compared with free-combination therapy. Consistent with these findings, current hypertension treatment guidelines recommend single-pill combination therapy in appropriate patients, based on its ability to simplify the treatment schedule and optimize compliance.

Conclusions
In conclusion, the results indicate that both valsartan/HCTZ and amlodipine/valsartan are excellent options for a broad range of hypertensive patients, including difficult-to-treat populations such as those with severe BP elevations, diabetes (and prediabetes), patients with the cardiometabolic syndrome, and individuals who are obese, elderly, or black. BP reductions with these combinations are greater than with the different monotherapy components alone, and both combinations are now indicated for first-line use in patients likely to need multiple drugs to achieve their BP goals. Although not discussed here, the clinician also has a number of other ARB-based single-pill combination treatments available (see Table 1) to ensure that a majority of patients with hypertension can attain their BP targets in a timely manner. These ARB-based combinations have the added advantage of good tolerability, with the ARB potentially reducing the adverse metabolic effects of HCTZ and the peripheral edema that may be associated with amlodipine.

Current treatment guidelines recommend first-line combination therapy for patients with stage 2 hypertension...
Doses available

**Diuretic combinations**
- Candesartan cilexetil/HCTZ (Atacand-HCT®)
  - 16/12.5 mg; 32/12.5 mg; 32/25 mg
- Eprosartan mesylate/HCTZ (Teveten HCT®)
  - 600/12.5 mg; 600/25 mg
- Irbesartan/HCTZ (Avalide®)
  - 150/12.5 mg; 300/12.5 mg
- Losartan/HCTZ (Hyzaar®)
  - 50/12.5 mg; 100/12.5 mg; 100/25 mg
- Olmesartan medoxomil/HCTZ (Benicar HCT®)
  - 20/12.5 mg; 40/12.5 mg; 40/25 mg
- Telmisartan/HCTZ (Micardis HCT®)
  - 40/12.5 mg; 80/12.5 mg; 80/25 mg
- Valsartan/HCTZ (Diovan-HCT®)
  - 160/12.5 mg; 160/25 mg; 320/12.5 mg; 320/25 mg

**Calcium channel blocker combinations**
- Amlodipine/valsartan (Exforge®)
  - 5/160 mg; 10/160 mg; 5/320 mg; 10/320 mg
- Amlodipine/olmesartan (Azor®)
  - 5/20 mg; 10/40 mg

*The single-pill combination is not approved for first-line use.

**Abbreviation:** HCTZ, hydrochlorothiazide.

**Table 1 Angiotensin receptor blocker single-pill combinations**

(SBP ≥ 160 mmHg and/or DBP ≥ 100 mmHg) or at high risk for cardiovascular events. ARB/diuretic or CCB/ARB combinations would be beneficial for most of these patients. In particular, RAAS inhibitor-based treatments are the preferred option for high-risk hypertensive patients with diabetes, metabolic syndrome, or kidney disease, for example. Some data suggest that black patients, who tend to have more severe hypertension than other racial groups, may respond less favorably than nonblacks to RAAS inhibitors. However, the need for combination therapy in a majority of black patients renders any differences in response to monotherapy inconsequential. The increased risk for ACE inhibitor-induced cough and angioedema among black patients may make ARB-based combinations more attractive.

Whether certain hypertensive populations will benefit more from one particular combination over another depends on several patient-related factors. For example, valsartan/HCTZ (or other ARB/HCTZ combinations) may be an adequate option for hypertensive patients without insulin resistance, whereas a CCB/RAAS blocker may be a preferred combination for the population with prediabetes, many of whom will need multiple antihypertensive agents. Diuretics are not preferred first-line treatment in patients with prediabetes or diabetes due to their negative metabolic effects. The findings of ACCOMPLISH, which included 11,506 patients (mean age, 68 years) with hypertension (mean baseline SBP/DBP, 145/80 mmHg) and high cardiovascular risk secondary to previous major events or presence of diabetes, suggest that a CCB/RAAS blocker combination may be a better option than a diuretic/RAAS blocker combination for this high-risk population.

In the future, novel RAAS-based combination therapies may become available (e.g., dual inhibition of AT1/endothelin receptors, AT1/thromboxane A2 receptors, and ACE/neutral endopeptidase). Further simplification of therapy and optimization of adherence may result from the incorporation of three drugs into a single pill. In addition, the possible benefits of combination antihypertensive therapy in reducing the risk of vascular dementia and cognitive dysfunction will undoubtedly be a focus of upcoming research.

**References**

21. Prevention of stroke by antihypertensive drug treatment in older


20. Prevention of cardiovascular disease and death with ramipril in a multiple-morbidity population (the VALIANT trial). Presented at the 22nd Annual Scientific Meeting of the American Society of Hypertension, May 19–22, 2007, Chicago, IL, USA.


43. Benz JR, Black HR, Graff A, Reed A, Fitzsimmons S, Shi Y. Valsartan in acute myocardial infarction (AMIS) study. Presented at the 22nd Annual Scientific Meeting of the American Society of Hypertension, May 19–22, 2007, Chicago, IL, USA.
For personal use only